Axcella Revenue and Competitors

Boston, MA USA

Location

$151.3M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Axcella's estimated annual revenue is currently $13.5M per year.(i)
  • Axcella's estimated revenue per employee is $499,444
  • Axcella's total funding is $151.3M.

Employee Data

  • Axcella has 27 Employees.(i)
  • Axcella grew their employee count by -64% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5.2M67-45%$107.3MN/A
#2
$0.2M10%N/AN/A
#3
$4.2M2735%N/AN/A
#4
$11.9M77-37%$312.8MN/A
#5
$1.4M929%N/AN/A
#6
$235M255-31%$340.9MN/A
#7
$45.9M237-7%$7.6MN/A
#8
$3.9M5035%N/AN/A
#9
$5.3M340%N/AN/A
#10
$1.9M12-8%N/AN/A
Add Company

Axcella is designing and developing novel endogenous metabolic modulator compositions to safely reprogram metabolic dysregulation. We are transforming the discovery and development of traditional drug and consumer health candidates from concept to clinical stages, by leveraging our deep understanding of human biology. Our novel approach rapidly gains unprecedented information in a capital efficient manner. Our platform has already produced a rich pipeline of product candidates in programs targeting liver, muscle, and CNS. Axcella Health was founded by Flagship Pioneering.

keywords:Biotechnology,Healthcare

$151.3M

Total Funding

27

Number of Employees

$13.5M

Revenue (est)

-64%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Axcella News

2022-04-06 - Should You Hold Axcella Health Inc (AXLA) in Biotechnology Industry?

Axcella Health Inc gets a 41 rank in the Biotechnology industry. Biotechnology is number 69 out of 148 industries. Overall Score - 39. AXLA has...

2022-03-30 - Axcella Therapeutics Reports Fourth Quarter and Full Year ...

Axcella is a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using compositions of endogenous metabolic...

2022-03-30 - Axcella Health Inc. (AXLA) CEO Bill Hinshaw on Q4 2021 Results - Earnings Call Transcript

Axcella Health Inc. (NASDAQ:AXLA) Q4 2021 Earnings Conference Call March 30, 2022 8:30 AM ET. Company Participants.

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$2.7M27N/AN/A
#2
$1.9M27-7%$5M
#3
$2.5M27-16%N/A
#4
$3.5M2713%N/A
#5
$3.4M27-21%N/A

Axcella Executives


NameTitle
Judi-Anne FoleyExecutive Assistant to President & CEO
William HinshawPresident and CEO
Tony TramontinChief Science Officer, Head of R&D
Alison SchecterPresident of R&D
Judi-Anne FoleyExecutive Assistant to President & CEO
Jason FredetteVice President, Investor Relations & Corp. Comm.
Margaret KozielVice President Clinical Development
Franklin VairinhosVice President Regulatory Affairs
William HinshawPresident and CEO